NSCLC patients may develop resistance to EGFR tyrosine kinase inhibitors (EGFR TKIs) via EGFR T790M mutation, HGF overexpression or MET amplification/overexpression [47, 48, 66]. This evidence concerns the gene HGF and non-small cell lung carcinoma.